Literature DB >> 16496177

Extracellular matrix remodeling in canine and mouse myocardial infarcts.

M Dobaczewski1, M Bujak, P Zymek, G Ren, M L Entman, N G Frangogiannis.   

Abstract

Extracellular matrix proteins not only provide structural support, but also modulate cellular behavior by activating signaling pathways. Healing of myocardial infarcts is associated with dynamic changes in the composition of the extracellular matrix; these changes may play an important role in regulating cellular phenotype and gene expression. We examined the time course of extracellular matrix deposition in a canine and mouse model of reperfused infarction. In both models, myocardial infarction resulted in fragmentation and destruction of the cardiac extracellular matrix, extravasation of plasma proteins, such as fibrinogen and fibronectin, and formation of a fibrin-based provisional matrix providing the scaffold for the infiltration of granulation tissue cells. Lysis of the plasma-derived provisional matrix was followed by the formation of a cell-derived network of provisional matrix composed of cellular fibronectin, laminin, and hyaluronic acid and containing matricellular proteins, such as osteopontin and osteonectin/SPARC. Finally, collagen was deposited in the infarct, and the wound matured into a collagen-based scar with low cellular content. Although the canine and mouse infarcts exhibited a similar pattern of extracellular matrix deposition, deposition of the provisional matrix was more transient in the mouse infarct and was followed by earlier formation of a mature collagen-based scar after 7-14 days of reperfusion; at the same timepoint, the canine infarct was highly cellular and evolving. In addition, mature mouse infarcts showed limited collagen deposition and significant tissue loss leading to the formation of a thin scar. In contrast, dogs exhibited extensive collagen accumulation in the infarcted area. These species-specific differences in infarct wound healing should be taken into account when interpreting experimental infarction studies and when attempting to extrapolate the findings to the human pathological process.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16496177     DOI: 10.1007/s00441-005-0144-6

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  70 in total

Review 1.  Extracellular Matrix in Ischemic Heart Disease, Part 4/4: JACC Focus Seminar.

Authors:  Nikolaos G Frangogiannis; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

2.  Immunohistochemical study on dystrophin expression in CAD-related sudden cardiac death: a marker of early myocardial ischaemia.

Authors:  Cristina Mondello; Luigi Cardia; Giovanni Bartoloni; Alessio Asmundo; Elvira Ventura Spagnolo
Journal:  Int J Legal Med       Date:  2018-05-07       Impact factor: 2.686

Review 3.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 4.  Biologic properties of endothelial progenitor cells and their potential for cell therapy.

Authors:  Pampee P Young; Douglas E Vaughan; Antonis K Hatzopoulos
Journal:  Prog Cardiovasc Dis       Date:  2007 May-Jun       Impact factor: 8.194

5.  Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion.

Authors:  Peter Vanderslice; Ronald J Biediger; Darren G Woodside; Wells S Brown; Sayadeth Khounlo; Navin D Warier; C William Gundlach; Amy R Caivano; William G Bornmann; David S Maxwell; Bradley W McIntyre; James T Willerson; Richard A F Dixon
Journal:  J Biol Chem       Date:  2013-05-23       Impact factor: 5.157

6.  Defective myofibroblast formation from mesenchymal stem cells in the aging murine heart rescue by activation of the AMPK pathway.

Authors:  Katarzyna A Cieslik; Joann Trial; Mark L Entman
Journal:  Am J Pathol       Date:  2011-08-03       Impact factor: 4.307

7.  Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.

Authors:  Iñigo Valiente-Alandi; Sarah J Potter; Ane M Salvador; Allison E Schafer; Tobias Schips; Francisco Carrillo-Salinas; Aaron M Gibson; Michelle L Nieman; Charles Perkins; Michelle A Sargent; Jiuzhou Huo; John N Lorenz; Tony DeFalco; Jeffery D Molkentin; Pilar Alcaide; Burns C Blaxall
Journal:  Circulation       Date:  2018-09-18       Impact factor: 29.690

8.  Infarct-derived chondroitin sulfate proteoglycans prevent sympathetic reinnervation after cardiac ischemia-reperfusion injury.

Authors:  Ryan T Gardner; Beth A Habecker
Journal:  J Neurosci       Date:  2013-04-24       Impact factor: 6.167

9.  Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction.

Authors:  Mark W M Schellings; Davy Vanhoutte; Melissa Swinnen; Jack P Cleutjens; Jacques Debets; Rick E W van Leeuwen; Jan d'Hooge; Frans Van de Werf; Peter Carmeliet; Yigal M Pinto; E Helene Sage; Stephane Heymans
Journal:  J Exp Med       Date:  2008-12-22       Impact factor: 14.307

10.  Thrombospondins in the heart: potential functions in cardiac remodeling.

Authors:  Mark W M Schellings; Geert C van Almen; E Helene Sage; Stephane Heymans
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.